UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
03 Mai 2024 - 2:00PM
Business Wire
Conference Call and Webcast Scheduled for
Monday, May 13, 2024, at 10:00AM ET
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
report 2024 first quarter financial results on Monday, May 13,
2024, prior to the open of the stock market. The announcement will
be followed by a live audio webcast and conference call at 10:00 AM
Eastern Time.
A live public webcast of the earnings conference call can be
accessed on UroGen’s Investor Relations website. Following the live
webcast, a replay will be available on the site for approximately
30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Jelmyto®
(mitomycin) for pyelocaliceal solution and investigational
treatment UGN-102 (mitomycin) for intravesical solution are
designed to ablate tumors by non-surgical means. UroGen is
headquartered in Princeton, NJ with operations in Israel. Visit
www.urogen.com to learn more or follow us on Twitter,
@UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240503850056/en/
INVESTORS: Vincent Perrone Senior Director, Investor Relations
vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA: Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024